Viral Infections

  • Author: Jin S. Suh, MD, FACP (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 7/26/16 (What's New)

References

Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al; CAPRISA 004 Trial Group. Effectiveness and safety of vaginal microbicide 1% tenofovir gel for prevention of HIV infection in women. Science. 2010;329:1168-1174.[Abdool Karim 2010]

Aguiar FS, Lopes DP, Bazin AR, Setúbal S, Cohen BJ, Nascimento JP. Human parvovirus B19 infection in HIV-positive patients. Rev Soc Bras Med Trop. 2001;34:239-242.[Aguiar 2001]

Albrecht H, Hoffmann C, Degen O, et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS. 1998;12:1149-1154.[Albrecht 1998]

Baeten JM, Lingappa J, Beck I, et al. Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons. J Infect Dis. 2011;203:117-121....

Action required

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.